Alpha Tau Medical Ltd. (DRTS)

NASDAQ: DRTS · IEX Real-Time Price · USD
2.965
+0.015 (0.51%)
At close: Feb 27, 2024, 3:59 PM
2.999
+0.034 (1.15%)
After-hours: Feb 27, 2024, 5:35 PM EST
0.51%
Market Cap 204.95M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 69.47M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,523
Open 2.920
Previous Close 2.950
Day's Range 2.920 - 3.030
52-Week Range 2.700 - 4.800
Beta 0.76
Analysts Strong Buy
Price Target 12.00 (+304.72%)
Earnings Date Mar 11, 2024

About DRTS

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 94
Stock Exchange NASDAQ
Ticker Symbol DRTS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for DRTS stock is "Strong Buy." The 12-month stock price forecast is $12.0, which is an increase of 304.72% from the latest price.

Price Target
$12.0
(304.72% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, t...

1 day ago - GlobeNewsWire

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

- The overview presentation will review some of the Company's recent achievements, including highly promising interim results from the Company's pancreatic cancer safety and feasibility trial as well ...

2 months ago - GlobeNewsWire

Alpha Tau to Participate in Sidoti Small-Cap Conference

JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, t...

3 months ago - GlobeNewsWire

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no product-related Serious Adverse Events -

3 months ago - GlobeNewsWire

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and HekaBio K.K. (“...

3 months ago - GlobeNewsWire

Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

- Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety and feasibility trial in similar indication currently underwa...

3 months ago - GlobeNewsWire

Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer

BOSTON--(BUSINESS WIRE)--Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced the appointment of Kathy Berg...

3 months ago - Business Wire

Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility

JERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, a...

4 months ago - GlobeNewsWire

Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel's Hadassah Medical Center

JERUSALEM, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, ...

5 months ago - GlobeNewsWire

Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

– Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April –

6 months ago - GlobeNewsWire

Alpha Tau Medical to Participate in September Investor Conferences

JERUSALEM, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, t...

6 months ago - GlobeNewsWire

Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

- 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete response rate. - Two-year local recurrence-free survival rate of 77%.

6 months ago - GlobeNewsWire

Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023

JERUSALEM, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, t...

7 months ago - GlobeNewsWire

Alpha Tau Medical to Participate in June Investor Conferences

JERUSALEM, May 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, to...

9 months ago - GlobeNewsWire

Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update

- Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer , which began enrolling patient s in March -

10 months ago - GlobeNewsWire

Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University

-First patient treated in the feasibility and safety study of intratumoral diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of new and recurrent squamous cell carcinoma of the...

10 months ago - GlobeNewsWire

Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open

JERUSALEM, May 11, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, an...

10 months ago - GlobeNewsWire

Alpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day

JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, to...

10 months ago - GlobeNewsWire

Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial

First patient treated in the feasibility and safety study of intratumoral diffusing alpha radiation emitters for the treatment of advanced inoperable pancreatic cancer. First patient treated in the fe...

11 months ago - GlobeNewsWire

Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit

JERUSALEM, March 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, ...

11 months ago - GlobeNewsWire

Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank

JERUSALEM, March 12, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, ...

1 year ago - GlobeNewsWire

Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update

Opened U.S. pivotal trial in recurrent cutaneous squamous cell carcinoma, which began enrolling patients in March.

1 year ago - GlobeNewsWire

Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

- First two US patients with recurrent cutaneous squamous cell carcinoma have been treated at University Cancer Center in Houston, Texas

1 year ago - GlobeNewsWire

Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases

JERUSALEM, March 01, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, ...

1 year ago - GlobeNewsWire

Alpha Tau to Participate in Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference

JERUSALEM, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, a...

1 year ago - GlobeNewsWire